MMP3 and pachyonychia congenita: By utilizing CA, we revealed that separate clinical features allocated PC patients to the high-risk group of BCR, including GGS ≥ 8, advanced T and N1 status, and PSA ≥ 20 ng/mL, which, consistent with the above, were considered indicators of an aggressive course of PC; in addition, these features corresponded to not only BCR itself but also the presence of the molecular ESR1 and MMP3 signature that was determined to anticipate unfavorable outcomes (Figure 3).